Jadenu (Deferasirox) Patent Expiration, LOE Window & CMS Spending
Jadenu (Deferasirox) by Novartis: FDA Orange Book core substance LOE 2034-11-21, 11 AB generics, $12.9M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N206910 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-11-21 |
| Last Listed Patent or Exclusivity Date | 2034-11-21 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 11 |
| 2024 CMS Total Public Spend | $12.9M |
| 2024 Medicare Part D Spend | $7.8M |
| 2024 Medicaid Spend | $5.1M |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 24.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.